




RealRate

PHARMACEUTICAL 2017

Alnylam Pharmaceuticals INC
Rank 116 of 308

Alnylam@20



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 55% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	671,877
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	131,699
Liabilities, Non-Current	3,067
Other Assets	476,361
Other Compr. Net Income	-37,810
Other Expenses	0
Other Liabilities	207,823
Other Net Income	61,638
Other Revenues	0
Property and Equipment	114,572
Research and Development	382,392
Selling, General and Administrative Expense	89,354

Output Variable	Value in 1000 USD
Assets	1,262,810
Liabilities	342,589
Expenses	471,746
Revenues	0
Stockholders Equity	920,221
Net Income	-410,108
Comprehensive Net Income	-429,013
BaseVar	1,088,296
ECR before Limited Liability	196%
Economic Capital Ratio	300%